← Leaderboards
Linda F Van Dyk
University Of Colorado Denver
$7,612,861
Attributed
$10,615,693
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,615,693 · 10
By mechanism
R01$9,343,185 · 5
R21$427,625 · 1
R56$367,998 · 1
T32$308,205 · 1
R03$153,680 · 1
R13$15,000 · 1
Top collaborators
- Eric T Clambey9 shared
- Hong W Chu5 shared
- Liwu Li5 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Elizabeth J Shpall$12,617,686
- Johan L Van Hove$1,132,395
- Mark Robert Nicolls$22,256,364
- Margaret E. Wierman$2,782,131
- Katja Kiseljakvassiliades$1,049,975
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionViralVirusCellsVirus DiseasesMalignant NeoplasmsKaposi SarcomaHuman Herpesvirus 8InflammatoryIn VitroIn VivoGammaherpesvirusImmuneHuman Herpesvirus 4PathogenesisMolecularCytokinePathogenChronicInsightBiological ModelsPathway InteractionsRegulationCell Type
Grant awards (38)
Therapeutic targets in gammaherpesvirus infection$549,993
R01 · FY2025 · AI · contact PI
Therapeutic targets in gammaherpesvirus infection$554,658
R01 · FY2024 · AI · contact PI
Therapeutic targets in gammaherpesvirus infection$77,633
R01 · FY2024 · AI · contact PI
Therapeutic targets in gammaherpesvirus infection$10,003
R01 · FY2024 · AI · contact PI
Therapeutic targets in gammaherpesvirus infection$573,985
R01 · FY2023 · AI · contact PI
Therapeutic targets in gammaherpesvirus infection$573,985
R01 · FY2022 · AI · contact PI
Molecular Pathogenesis of Infectious Diseases$160,649
T32 · FY2022 · AI · contact PI
24th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents$15,000
R13 · FY2022 · CA · contact PI
Therapeutic targets in gammaherpesvirus infection$545,303
R01 · FY2021 · AI · contact PI
Molecular Pathogenesis of Infectious Diseases$147,556
T32 · FY2021 · AI · contact PI
Non-coding RNAs in Gammaherpesvirus Infection and Disease$385,420
R01 · FY2019 · AI · contact PI
IRAK-M in lung defense against rhinovirus infection$398,037
R01 · FY2018 · AI
Non-coding RNAs in Gammaherpesvirus Infection and Disease$385,420
R01 · FY2018 · AI · contact PI
Single cell analysis of virus and host gene expression in gammaherpesvirus infection$194,375
R21 · FY2018 · AI · contact PI
IRAK-M in lung defense against rhinovirus infection$398,037
R01 · FY2017 · AI
Non-coding RNAs in Gammaherpesvirus Infection and Disease$385,420
R01 · FY2017 · AI · contact PI
Single cell analysis of virus and host gene expression in gammaherpesvirus infection$233,250
R21 · FY2017 · AI · contact PI
IRAK-M in lung defense against rhinovirus infection$399,799
R01 · FY2016 · AI
Non-coding RNAs in Gammaherpesvirus Infection and Disease$385,420
R01 · FY2016 · AI · contact PI
Cyclin requirements in gammaherpesvirus infection and disease$308,843
R01 · FY2016 · CA · contact PI
IRAK-M in lung defense against rhinovirus infection$404,458
R01 · FY2015 · AI
Cyclin requirements in gammaherpesvirus infection and disease$309,073
R01 · FY2015 · CA · contact PI
IRAK-M in lung defense against rhinovirus infection$419,028
R01 · FY2014 · AI
Cyclin requirements in gammaherpesvirus infection and disease$298,913
R01 · FY2014 · CA · contact PI
Cyclin requirements in gammaherpesvirus infection and disease$288,808
R01 · FY2013 · CA · contact PI
Regulation of Herpesvirus Infection by Viral miRNAs$367,998
R56 · FY2012 · AI · contact PI
Cyclin requirements in gammaherpesvirus infection and disease$306,328
R01 · FY2012 · CA · contact PI
Characterization of an animal model of chronic infection and disease$76,715
R03 · FY2010 · AI · contact PI
Characterization of an animal model of chronic infection and disease$76,965
R03 · FY2009 · AI · contact PI
In Vivo Analysis of Viral Cyclin$233,802
R01 · FY2008 · CA · contact PI
In Vivo Analysis of Viral Cyclin$49,804
R01 · FY2008 · CA · contact PI
In Vivo Analysis of Viral Cyclin$233,967
R01 · FY2007 · CA · contact PI
In Vivo Analysis of Viral Cyclin$48,354
R01 · FY2007 · CA · contact PI
In Vivo Analysis of Viral Cyclin$241,120
R01 · FY2006 · CA · contact PI
In Vivo Analysis of Viral Cyclin$46,947
R01 · FY2006 · CA · contact PI
In Vivo Analysis of Viral Cyclin$247,087
R01 · FY2005 · CA
In Vivo Analysis of Viral Cyclin$33,774
R01 · FY2005 · CA
In Vivo Analysis of Viral Cyclin$249,766
R01 · FY2004 · CA